7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $17.9B | -$3.7B | 35.3% | -16.3% | -6.5% | -5.3% | -$5.3B | — | $33.6B |
| 2024 | $23.0B | -$8.7B | 26.4% | -34.8% | -19.2% | -12.8% | -$9.7B | — | $29.5B |
| 2023 | $32.3B | -$6.6B | 31.9% | -12.3% | -23.5% | -15772.6% | $1.1B | — | $5.3B |
| 2022 | $40M | -$8M | 54.5% | -17.5% | -0.0% | -13.3% | -$1M | — | $5.7B |
| 2021 | $48M | $11M | 52.8% | 28.3% | 24.1% | 16.1% | -$3M | — | $8M |
| 2020 | $31M | $8M | 45.9% | 33.4% | 36.3% | 26.2% | $6M | — | $10M |
| 2019 | $33M | — | 40.3% | 29.4% | 0.0% | — | $13M | — | $3M |
How the market has priced UPC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Universe Pharmaceuticals INC's revenue has grown 257.2% per year. These are computed facts, not advice.
As of FY2025, Universe Pharmaceuticals INC reported — of total debt against $33.6B of cash; operating income covered interest expense -10.1×.
In FY2025, gross margin was 35.3%, operating margin -16.3%, and net margin -20.6%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.